GRIDD has two Boards - a Development Board to assist with its development and funding, and a Scientific Advisory Board to advise on its scientific research direction.
GRIDD’s Development Board harnesses the passion and commitment of its members to identify, develop and deliver new funding opportunities to maximise the Institute’s work tackling devastating diseases.
The Board Chairman is Mr Peter Johnstone, who is also CEO at The Clem Jones Group. Peter’s background in philanthropy includes six years as CEO at the Leukaemia Foundation in Brisbane and The Clem Jones Group for more than 5 years. The Clem Jones Group is a Queensland funding organisation that manages the activities of The Clem Jones Foundation, based on the philanthropy of the remarkable Brisbane Lord Mayor (1961-75) who passed away in 2007.
Members of the Development Board, who will serve for three years, include Ms Rhonda White AO and Mr Gary Toomey.
Ms White is co-founder of the Terry White Chemists Group and has been integral to the success of the brand. She is currently a board member of the Terry White Group Limited, a Trustee of the Queensland Performing Arts Trust (QPAT) and a member of the National Gallery of Australia Council. She has been a director of government and private companies, including Ergon Energy and Energex Retail, and was Foundation Chair of the Queensland Cancer Fund Volunteers Committee.
Mr Toomey has worked as both a Chief Executive Officer and Chief Financial Officer for several large multinational companies. He is currently Executive Chairman of CTOB Management Pty Ltd and CEO of the Bangarra Group. He has been a Director of several large listed companies including Australia New Zealand Banking Group Ltd and Qantas Airways Ltd.
The Board members’ voluntary work includes advocating for GRIDD, developing strong networks and laying foundations for improved philanthropic ventures, including identifying those who want to make a financial difference in bringing new drug treatments to people globally. The Board’s Terms of Reference emphasise the importance of its role as a fundraising and philanthropy support to GRIDD.
“GRIDD has the experience, infrastructure, resources and maturity to lead new drug discovery. The Development Board will bring its connections into play to help GRIDD identify and deliver new funding sources to support its work in tackling devastating diseases globally.” Peter Johnstone, CEO of Clem Jones Group, Chair of GRIDD Development Board.
Scientific Advisory Board
Dr Rob Don has been appointed as Chair of the SAB and other members include Emeritus Professor Susan Hamilton and Dr Jane Andrews. Members will serve for 12 months.
Dr Don is the recently retired Discovery & Preclinical Director for the global organisation Drugs for Neglected Diseases Initiative (DNDi - created in 2005 by Medecins sans Frontieres). Over a period of 12 years he built a pipeline of new chemical entities reaching Phase Three clinical trials for a number of infectious tropical diseases. Dr Don was a member of the Scientific Advisory Committees of the Genomics Institute of the Novartis Research Foundation, the Liverpool School of Tropical Medicine, the Bill and Melinda Gates Foundation, and Anacor (recently purchased by Pfizer). Prior to joining DNDi, Dr Don was Senior Vice President for Research and Clinical Development at the Australian based biotechnology company, Progen Pharmaceuticals for 10 years.
Emeritus Professor Hamilton has had a career in biochemistry research at the University of Queensland, with applications from medicine to agriculture. She was President of the Academic Board of UQ and prior to that held roles of Deputy President of the Academic Board, and Associate Dean (Academic) of the Faculty of Biological and Chemical Sciences at UQ. Emeritus Professor Hamilton was Chair of the Education Committee of the International Union of Biochemistry and Molecular Biology (IUBMB) from 2006 – 2012. She is committed to improving career outcomes for women in science, through the activities of the Gender Equity Subcommittee at UQ, membership of the Science, Engineering and Technology Taskforce (Qld Government) and her roles on IUBMB.
Dr Jane Andrews is a founder and investor in numerous innovative companies, and has extensive experience in corporate strategy, entrepreneurship, commercialisation, innovation, research and development. Dr Andrews is a Graduate of the Australian Institute of Company Directors, holds a PhD in Life Sciences, a Bachelor of Science (First Class Honours) and a Graduate Diploma in Applied Finance and Investment. Jane is a Non-Executive Director of TechnologyOne Limited.